Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 1;9(1):170.
doi: 10.1186/s13756-020-00838-y.

β-lactamase-mediated resistance in MDR-Pseudomonas aeruginosa from Qatar

Mazen A Sid Ahmed  1   2 , Faisal Ahmad Khan  3 , Ali A Sultan  4 , Bo Söderquist  5 , Emad Bashir Ibrahim  6   4 , Jana Jass  3 , Ali S Omrani  7   8
Affiliations

β-lactamase-mediated resistance in MDR-Pseudomonas aeruginosa from Qatar

Mazen A Sid Ahmed et al. Antimicrob Resist Infect Control. .

Abstract

Background: The distribution of β-lactam resistance genes in P. aeruginosa is often closely related to the distribution of certain high-risk international clones. We used whole-genome sequencing (WGS) to identify the predominant sequence types (ST) and β-lactamase genes in clinical isolates of multidrug-resistant (MDR)-P. aeruginosa from Qatar METHODS: Microbiological identification and susceptibility tests were performed by automated BD Phoenix™ system and manual Liofilchem MIC Test Strips.

Results: Among 75 MDR-P. aeruginosa isolates; the largest proportions of susceptibility were to ceftazidime-avibactam (n = 36, 48%), followed by ceftolozane-tazobactam (30, 40%), ceftazidime (n = 21, 28%) and aztreonam (n = 16, 21.3%). All isolates possessed Class C and/or Class D β-lactamases (n = 72, 96% each), while metallo-β-lactamases were detected in 20 (26.7%) isolates. Eight (40%) metallo-β-lactamase producers were susceptible to aztreonam and did not produce any concomitant extended-spectrum β-lactamases. High risk ST235 (n = 16, 21.3%), ST357 (n = 8, 10.7%), ST389 and ST1284 (6, 8% each) were most frequent. Nearly all ST235 isolates (15/16; 93.8%) were resistant to all tested β-lactams.

Conclusion: MDR-P. aeruginosa isolates from Qatar are highly resistant to antipseudomonal β-lactams. High-risk STs are predominant in Qatar and their associated MDR phenotypes are a cause for considerable concern.

Keywords: Beta-lactamases; MDR; P. aeruginosa; ST235.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Antimicrobial susceptibility testing results for 75 MDR-P. aeruginosa isolates from Qatar. Columns represent number (Y axis) of isolates susceptible and line represents percentage (Z axis) of isolates susceptible to the corresponding antipseudomonal β-lactam. Reporting is based on CLSI breakpoint recommendations (M100, 30th edition—January 2020). ATM, aztreonam; CAZ, ceftazidime; CZA, ceftazidime-avibactam; C/T, ceftolozane-tazobactam; FEP, cefepime; MEM, meropenem; MIC, minimum inhibitory concentration in µg/mL, TZP, piperacillin-tazobactam
Fig. 2
Fig. 2
Distribution of sequence types of MDR-P. aeruginosa (n = 75) isolated in Qatar from 2014 to 2017
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Horcajada JP, Montero M, Oliver A, Sorli L, Luque S, Gomez-Zorrilla S, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32(4):e00031–e119. - PMC - PubMed
    1. Oliver A, Mulet X, Lopez-Causape C, Juan C. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat. 2015;21–22:41–59. - PubMed
    1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. - PubMed
    1. Bush K. The ABCD’s of β-lactamase nomenclature. J Infect Chemother. 2013;19(4):549–559. - PubMed
    1. Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis. 2017;65(1):110–120. - PMC - PubMed

Publication types

MeSH terms